Actively Recruiting
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Led by AstraZeneca · Updated on 2026-04-22
590
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This non-interventional, cross-sectional study aims to investigate treatment preferences from a sample of physicians and patients with experience of 1L EGFR-TKI for stage IV NSCLC by administering a survey, which primarily includes a DCE approach.
CONDITIONS
Official Title
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
The following inclusion criteria must be met in order to be enrolled in the stage 1:
Patient:
- Provide informed consent
- 18 years or older
- Diagnosed with stage IV NSCLC
- Currently receiving or previously received 1L EGFR-TKI treatment
- Without communication barrier
- Do not exhibit signs of cognitive impairment that would prevent participation in an interview, as informally assessed during screening by the recruiter
Physician:
- Provide informed consent
- Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
- Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
- Holding the title of associate chief physician or higher
The following inclusion criteria must be met in order to be enrolled in the stage 2:
Patient:
- Provide informed consent
- 18 years or older
- Diagnosed with stage IV NSCLC
- Currently receiving or previously received 1L EGFR-TKI treatment
- Without communication barrier
- Do not exhibit signs of cognitive impairment that would prevent participation in a survey, as informally assessed during screening by the recruiter
Physician:
- Provide informed consent
- Specialized in departments of medical oncology, respiratory medicine, or thoracic surgery at tertiary hospitals
- Manage at least 3 stage IV NSCLC patients with 1L EGFR-TKI per month
- Holding the title of attending physician or higher
You will not qualify if you...
Not applicable.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site
Chengdu, China, 610000
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here